Table 1.
Viral yield in culture supernatants of SARS-CoV-infected Raji cells
| Sample and treatment | Time (h) postinfection | Viral titer (log10 TCID50/ml) | Mean no. (log10) ± SD |
|
|---|---|---|---|---|
| ORF1b gene copies | Nucleocapsid gene copies | |||
| SARS-CoV inoculum (no treatment) | 3 | 3.28 ± 0.04 | 3.41 ± 0.07 | |
| 5 | 5.39 ± 0.04 | 5.51 ± 0.08 | ||
| 6 | 6.76 ± 0.05 | 6.94 ± 0.07 | ||
| Cell culture supernatant from Raji cells | ||||
| No treatment | 6 to 72 | NDa | 0 | 0 |
| SARS-CoV + 1/1,000 control serum | 6 | ND | 3.05 ± 0.15 | 3.56 ± 0.37 |
| 24 | ND | 3.24 ± 0.13 | 3.84 ± 0.46 | |
| 48 | ND | 3.10 ± 0.03 | 3.50 ± 0.53 | |
| 72 | ND | 3.30 ± 0.04 | 3.65 ± 0.43 | |
| SARS-CoV + 1/1,000 anti-S serum | 6 | ND | 3.36 ± 0.14 | 3.89 ± 0.41 |
| 24 | ND | 2.84 ± 0.14 | 3.46 ± 0.50 | |
| 48 | ND | 3.26 ± 0.04 | 3.67 ± 0.50 | |
| 72 | ND | 3.43 ± 0.03 | 3.73 ± 0.38 | |
a
ND, not determined. The TCID50 titration was not possible due to the presence of neutralizing immune serum in some cell culture supernatants. Results are shown as means ± the SD of four samples from two independent measurements.